Outpace Bio, Inc.

Developer of protein and cell technologies that enable curative cell therapies

Outpace Bio, led by Scott Boyken and Marc Lajoie, was spun out of Lyell Immunopharma in 2020 to develop protein solutions for cell therapy. The company is using its platform to design proteins with new biological functions like kill switches, ultra-specific cell targeting, T-cell exhaustion prevention and cytokine regulation. These novel functions are designed to respond to the environment and to drugs to enable greater potential for cell therapies. Lyell is the founding investor and is joined by a group of dedicated life science investors.